Montefiore Einstein Center for Cancer Care | Strategic Alliance Partners

Latest from Montefiore Einstein Center for Cancer Care


Cancer Dormancy and Tumor Microenvironment Institute to Take Research Efforts to Greater Heights

October 29, 2021

The Cancer Dormancy and Tumor Microenvironment Institute, which has recently been launched at Albert Einstein Cancer Center, will focus on taking the tumor microenvironment research being done at the center to the next level and to develop novel technologies that can better identify dormant cancer as well as prevent and control recurrent disease.

Focus on Health Equity in Cancer Care Leads to National Recognition

August 26, 2021

Montefiore Einstein Cancer Center has once again earned national recognition for its quality of care studies leading to enhanced patient care, its strong cancer screening and early detection initiatives, and its exceptional support services.

Lauren Hackett, MPA, to Lead Operations at NCI-Designated Albert Einstein Cancer Center

June 25, 2021

Albert Einstein Cancer Center, Albert Einstein College of Medicine, and Montefiore Health System announced that Lauren Hackett, MPA, has been appointed the deputy director of administration of AECC and associate vice president of cancer medicine at Montefiore Medicine.

Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer

June 24, 2021

Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.

Prominent Scientist Julio Aguirre-Ghiso, Ph.D., To Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

June 16, 2021

Leading cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program.

Halmos Zeroes in on Year Ahead for Lung Cancer Treatment

December 15, 2020

Balazs Halmos, MD discusses the year 2021 and how it will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA into a more minimal residual disease–based setting.